



IDEAYA Biosciences

Improving Lives
Through Transformative
Precision Medicines

NASDAQ: **IDYA**
November 2023

IDEAYA Highlights

Breakthrough Science on transformative programs in precision medicine, including Synthetic Lethality – an emerging area of precision medicine

Broad Pipeline of potential *first-in-class* precision medicine oncology programs with defined patient biomarkers

Proven Management Team with deep business and scientific experience has built leading oncology companies

Pharma Strategic Partnerships with GlaxoSmithKline¹, including ~\$2 billion in potential cash milestones, Pfizer² and Amgen³

Strong Balance Sheet of ~\$656 million⁴ with capital efficient model

Analyst Coverage by Capital One, Citi, Goldman Sachs, Guggenheim, Jefferies, JP Morgan, Leerink, Oppenheimer, RBC, Stifel and Wedbush

- (1) GSK Collaboration, Option and License Agreement
- (2) Pfizer Clinical Trial Collaboration and Supply Agreements
- (3) Amgen Clinical Trial Collaboration and Supply Agreement
- (4) Includes aggregate of \$511.1M cash, cash equivalents and marketable securities as of September 30, 2023, \$134.7M estimated net proceeds from closing of underwritten public offering on October 27, 2023, and \$10.0M receivable from GSK milestones